Vincristine, Dactinomycin, and Lower Doses of Cyclophosphamide With or Without Radiation Therapy for Patients With Newly Diagnosed Low-Risk Embryonal/Botryoid/Spindle Cell Rhabdomyosarcoma

This phase III trial is studying how well combination chemotherapy and radiation therapy work
in treating patients with newly diagnosed low-risk rhabdomyosarcoma. Drugs used in
chemotherapy, such as vincristine, dactinomycin, and cyclophosphamide, work in different ways
to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses
high-energy x-rays to damage tumor cells. Combining chemotherapy with radiation therapy may
kill more tumor cells. It is not yet known which treatment regimen is more effective in
treating low-risk rhabdomyosarcoma.